Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)
- Status
- RECRUITING
- Phase
- PHASE2
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- COMPLETED
- Phase
- PHASE2
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)
- Status
- TERMINATED
- Phase
- PHASE1
ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases
- Status
- TERMINATED
- Phase
- PHASE2
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
- Status
- WITHDRAWN
- Phase
- PHASE2
Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3